Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790907 · ClinicalTrials.gov registry record · Phase 4
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 3,235
- Enrollment target
NCT00790907: Completed Phase 4 study, sponsored by GlaxoSmithKline.
NCT00790907 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 3,235 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (525% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00790907, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3,235 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST segment elevation myocardial infarction) who have been initially treated with fondaparinux.
Primary Outcome
The peri-percutaneous coronary intervention (peri-PCI) period was defined as the period during the time from randomization up to 48 hours after the end of the PCI procedure, typically 49 hours total. Major and minor bleeding events were adjudicated by a blinded central independent adjudication committee (CIAC). Major vascular access site complications comprised large hematoma, pseudoaneurysm requiring treatment, aterio-venous fistula, or other vascular procedures related to the access site.
Interventions
- DRUG fondaparinux background and standard dose UFH
- DRUG Fondaparinux background and low dose heparin
- DRUG Open label fondaparinux
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,235 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
What the finished NCT00790907 record still lists
NCT00790907 is an interventional study that assigns participants to a tested intervention. Its 3,235 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (525% higher).
The record links to 0 conditions, and to 3 interventions - of which fondaparinux background and standard dose UFH is the first listed.
NCT00790907 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00790907 about?
NCT00790907 is a clinical study titled "Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)". The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST segment elevation myocardial infarction) who have been initially treated ...
What is the current status of trial NCT00790907?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3,235 participants. The study started on 2009-02. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00790907?
The interventions under investigation include: fondaparinux background and standard dose UFH (DRUG), Fondaparinux background and low dose heparin (DRUG), Open label fondaparinux (DRUG).
Who is sponsoring clinical trial NCT00790907?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00790907's enrollment target sits among peer trials
3,235 24th of 2000 higher than 1,977 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06953375 · 3,250 participants · NA
Implementation of Neuromuscular Electrical Stimulation After Total Knee Arthroplasty
- NCT06587529 · 3,218 participants · NA
Rigorous Evaluation of the READY to Stand Curriculum to Prevent the Commercial Sexual Exploitation of Children
- NCT06760507 · 3,209 participants · NA
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
- NCT04077762 · 3,266 participants · NA
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia